

*A1  
Candt*

33. The method of claim 32 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

34. The method of claim 1 wherein said micellar drug carrier is an AB-diblock copolymer.

35. The method of claim 34 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

36. The composition of claim 9 wherein said micellar drug carrier is an AB-diblock copolymer.

37. The composition of claim 36 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

38. The method of claim 16 wherein said micellar drug carrier is an AB-diblock copolymer.

39. The method of claim 38 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

40. A method for delivery of a drug to a selected site in a patient comprising:

*A  
Cantt*

(a) administering to said patient a composition comprising a micellar drug carrier having a hydrophobic core, wherein said micellar drug carrier comprises a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer, and an effective amount of said drug disposed in said hydrophobic core; and

(b) applying ultrasonic energy to said selected site such that said drug is released from said hydrophobic core to said selected site.

41. The method of claim 40 wherein said poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer has a molecular weight of about 6500.

42. The method of claim 40 wherein said drug is hydrophobic.

43. The method of claim 42 wherein said hydrophobic drug is an anthracycline.

44. The method of claim 43 wherein said anthracycline is doxorubicin.

45. The method of claim 43 wherein said anthracycline is  
ruboxyl.

46. A composition for delivery of a hydrophobic drug to a  
selected site in a patient comprising a micellar drug carrier  
having a hydrophobic core, wherein said micellar drug carrier  
comprises a poly(ethylene oxide)-poly(propylene oxide)-  
poly(ethylene oxide) block copolymer, and an effective amount of  
said hydrophobic drug disposed in said hydrophobic core.

47. The composition of claim 46 wherein said poly(ethylene  
oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer  
has a molecular weight of about 6500.

48. The composition of claim 46 wherein said hydrophobic drug  
is an anthracycline.

49. The composition of claim 48 wherein said anthracycline is  
doxorubicin.

50. The composition of claim 48 wherein said anthracycline is  
ruboxyl.

51

A method for enhancing uptake of a drug by cells at a selected site in a patient comprising:

(a) administering to said patient a composition comprising a micellar drug carrier having a hydrophobic core, wherein said micellar drug carrier comprises a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer, and an effective amount of said drug disposed in said hydrophobic core; and

(b) applying ultrasonic energy to said selected site such that said drug is released from said hydrophobic core and taken up by said cells.

52. The method of claim 51 wherein said poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer has a molecular weight of about 6500.

53. The method of claim 51 wherein said drug is hydrophobic.

54. The method of claim 53 wherein said hydrophobic drug is an anthracycline.

55. The method of claim 54 wherein said anthracycline is doxorubicin.

*Antist*

56. The method of claim 54 wherein said anthracycline is ruboxyl.

57. A method for reducing side effects in a patient from administration of a drug comprising:

(a) administering to said patient a composition comprising a micellar drug carrier having a hydrophobic core, wherein said micellar drug carrier comprises a poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer, and an effective amount of said drug disposed in said hydrophobic core; and

(b) applying ultrasonic energy to said patient such that said drug is released from said hydrophobic core.

58. The method of claim 57 wherein said poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer has a molecular weight of about 6500.

59. The method of claim 57 wherein said drug is hydrophobic.

60. The method of claim 59 wherein said hydrophobic drug is an anthracycline.